This is an international site for Sandostatin® LAR® and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Sandostatin LAR Information for US residents Sandostatin LAR Information for International Healthcare Professionals Sandostatin LAR Information for Patients Outside the US

Sandostatin® LAR® Delivers Powerful Efficacy and Unparalleled Evidence
Home > About Sandostatin® LAR® > Why Use Sandostatin® LAR®?

Why Use Sandostatin® LAR®?

Sandostatin® demonstrates unparalleled efficacy, safety, and results for GEP NET patients.1,2

  • 42% reduction in diarrhoea frequency *1,2
  • 84% reduction in flushing frequency*1,2
  • Demonstrated disease stabilisation in some patients†3
  • Up to 50% suppression of 5-HIAA*2,3

Read more about GEP NETs

Sandostatin, the leading somatostatin analogue in the world, is proven effective and safe in treating acromegaly.

  • Up to 68% of patients experienced both GH <2.5 ng/mL + IGF-1 normalisation4
  • Up to 72% of patients experienced reduction of GH <2.5 ng/mL4
  • Up to 75% of patients experienced IGF-1 normalisation4
  • Up to 75% of patients experienced significant tumour shrinkage5

Read more about acromegaly

Sandostatin provides the experience your patients need.

  • Over 600,000 patient-years of experience‡§6
  • Over 6000 published articles‡§6,7
  • Over 600 clinical trials‡§6,7

Sandostatin offers the benefit of 1 type of therapy, available in 2 formulations. Sandostatin Injection, approved for use since 1987, is a subcutaneous (SC) formulation of the drug octreotide acetate. Sandostatin LAR, the long-acting formulation of this drug, was approved for use in 1997 and maintains all of the clinical and pharmacological characteristics of the immediate-release dosage form of SC Sandostatin Injection. Sandostatin LAR provides the added feature of convenient, once-monthly administration and has a well-tolerated safety profile backed by more than a decade of clinical use.

Sandostatin Timeline

Mechanism of action for acromegaly

View the video on the Sandostatin LAR mechanism of action for acromegaly.



 


Mechanism of action for GEP NETs

View a video on the Sandostatin LAR mechanism of action for GEP NETs.



 


*In the treatment of carcinoid syndrome.
†Results from a phase II multicentre study.
‡Includes both ongoing and completed trials in acromegaly and functional
 GEP NETs.
§Combined experience with immediate release Sandostatin® and
 Sandostatin® LAR®.

References: 1. Sandostatin® LAR® Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008. 2. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606. 3. Arnold R, Trautmann ME, Creutzfeldt W, et al; and the German Sandostatin Multicentre Study Group. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430-438. 4. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88:3090-3098. 5. Mercado M, Borges F, Bouterfa H, et al; on behalf of the SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol. 2007;66:859-868. 6. Data on file, Novartis Pharma AG. 7. PubMed [database online]. National Center for Biotechnology Information. Available at: http://www.ncbi.nlm.nih.gov/sites/gquery?term=sandostatin. Accessed March 19, 2009.


sandostatin.com